CLASS ACTION UPDATE for ICPT, TILE and BABA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / December 24, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ICPT Shareholders Click Here: https://www.zlk.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=11801&wire=1
TILE Shareholders Click Here: https://www.zlk.com/pslra-1/interface-inc-loss-submission-form?prid=11801&wire=1
BABA Shareholders Click Here: https://www.zlk.com/pslra-1/alibaba-group-holding-limited-loss-submission-form?prid=11801&wire=1

* ADDITIONAL INFORMATION BELOW *

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)

ICPT Lawsuit on behalf of: investors who purchased September 28, 2019 - October 7, 2020
Lead Plaintiff Deadline : January 4, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=11801&wire=1

According to the filed complaint, during the class period, Intercept Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

Interface, Inc. (NASDAQ: TILE)

TILE Lawsuit on behalf of: investors who purchased March 2, 2018 - September 28, 2020
Lead Plaintiff Deadline : January 11, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/interface-inc-loss-submission-form?prid=11801&wire=1

According to the filed complaint, during the class period, Interface, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Interface had inadequate disclosure controls and procedures and internal control over financial reporting; (ii) consequently, Interface, inter alia, reported artificially inflated income and earnings per share ("EPS") in 2015 and 2016; (iii) Interface and certain of its employees were under investigation by the SEC with respect to the foregoing issues since at least as early as November 2017, had impeded the SEC's investigation, and downplayed the true scope of the Company's wrongdoing and liability with respect to the SEC investigation; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Alibaba Group Holding Limited (NYSE: BABA)

BABA Lawsuit on behalf of: investors who purchased July 20, 2020 - November 3, 2020
Lead Plaintiff Deadline : January 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/alibaba-group-holding-limited-loss-submission-form?prid=11801&wire=1

According to the filed complaint, during the class period, Alibaba Group Holding Limited made materially false and/or misleading statements and/or failed to disclose that: (1) Ant Small and Micro Financial Services Group Co., Ltd. ("Ant Group"), a financial technology company in which Alibaba owns a 33% equity interest, did not meet listing qualifications or disclosure requirements for certain material matters; (2) certain impending changes in the Fintech regulatory environment would impact Ant Group's business; (3) as a result of the foregoing, Ant Group's initial public offering was reasonably likely to be suspended; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/622311/CLASS-ACTION-UPDATE-for-ICPT-TILE-and-BABA-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.